(Q34240913)

31 July 2017

1 reference

title

Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues (English)

1 reference

31 July 2017

Arun B

1

1 reference

31 July 2017

Frenkel EP

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

491-505

1 reference

Biochemical and biophysical analyses of recombinant forms of human topoisomerase I

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

Topoisomerase I inhibitors: review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.3.491

21 January 2018

Identifiers

DOI

10.1517/14656566.2.3.491

1 reference

31 July 2017

1 reference